ARS Pharmaceuticals, Inc. (SPRY), on Thursday announced that the FDA has approved neffy 1 mg (epinephrine nasal spray) for the treatment of Type I allergic reactions, including anaphylaxis, in pediatric patients aged 4 years and older who weigh 15 to less than 30 kilograms.
This approval marks the first needle-free epinephrine treatment for this age group in over 35 years, addressing an unmet need for children and caregivers who fear using traditional needle-based auto-injectors.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.